Wall Street analyst estimates for Protalix BioTherapeutics, Inc. (PLX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.71 |
Valuation Ratios
| P/E Ratio | 11.12 |
| Price / Book | 3.00 |
| EV / EBITDA | 7.49 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.2M | $21.1M | $34.2M | $54.7M | $62.9M | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Cost of Revenue | $8.4M | $15.2M | $9.3M | $10.9M | $10.9M | $16.3M | $19.6M | $23.0M | $24.3M | $27.5M |
| Gross Profit | $801000 | $5.8M | $24.9M | $43.8M | $52.0M | $22.0M | $28.0M | $42.5M | $29.1M | $25.2M |
| Research & Development | $30.4M | $28.8M | $33.3M | $44.6M | $38.2M | $29.7M | $29.3M | $17.1M | $13.0M | $19.1M |
| Selling, General & Admin | $9.4M | $11.5M | $10.9M | $9.9M | $11.1M | $12.7M | $11.7M | $15.0M | $12.2M | $11.7M |
| Operating Expenses | $34.0M | $40.4M | $44.2M | $54.5M | $49.3M | $42.5M | $41.1M | $32.1M | $25.2M | $30.7M |
| Operating Income | -$33.2M | -$34.5M | -$19.3M | -$10.7M | $2.7M | -$20.5M | -$13.0M | $10.5M | $3.9M | -$5.5M |
| EBITDA | -$23.0M | -$71.8M | -$17.1M | -$8.7M | $4.5M | -$18.9M | -$10.8M | $12.9M | $6.5M | -$3.0M |
| Interest Expense | $4.2M | $9.7M | $7.7M | $8.0M | $9.7M | $7.5M | $2.5M | $3.2M | $1.1M | $1.2M |
| Pre-tax Income | -$29.2M | -$83.4M | -$26.5M | -$18.3M | -$6.5M | -$27.6M | -$14.4M | $8.6M | $4.2M | -$5.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | $530000 | $254000 | $1.2M | $996000 |
| Net Income | -$29.4M | -$83.4M | -$26.5M | -$18.3M | -$6.5M | -$27.6M | -$14.9M | $8.3M | $2.9M | -$6.6M |
| EPS | $-0.29 | $-6.50 | $-1.80 | $-1.23 | $-0.22 | $-0.62 | $-0.31 | $0.12 | $0.04 | $-0.08 |
| EPS (Diluted) | $-0.29 | $-6.50 | $-1.80 | $-1.23 | $-0.22 | $-0.62 | $-0.31 | $0.10 | $0.04 | $-0.08 |
| Shares Outstanding (Diluted) | $101.4M | $13.1M | $14.7M | $14.8M | $29.1M | $44.1M | $48.5M | $82.4M | $81.1M | $78.5M |
Price
| Price | $2.68 |
| Market Cap | $216M |
| Exchange | AMEX |
| Country | US |
Related companies: CDXS · CHRS · GNFT · IVVD · MDWD · NTHI · OABI
Explore sector: Healthcare · Biotechnology
More sections of PLX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks